Symbol="EIGR"
AssetType="Common Stock"
Name="Eiger Biopharmaceuticals Inc"
Description="Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. The company is headquartered in Palo Alto, California."
CIK="1305253"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="2155 PARK BOULEVARD, PALO ALTO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="34626500"
EBITDA="-92890000"
PERatio="None"
PEGRatio="0"
BookValue="0.796"
DividendPerShare="0"
DividendYield="0"
EPS="-2.31"
RevenuePerShareTTM="0.34"
ProfitMargin="0"
OperatingMarginTTM="-6.24"
ReturnOnAssetsTTM="-0.461"
ReturnOnEquityTTM="-1.463"
RevenueTTM="14929000"
GrossProfitTTM="11647000"
DilutedEPSTTM="-2.31"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.541"
AnalystTargetPrice="3.33"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="3.551"
PriceToBookRatio="0.76"
EVToRevenue="8.36"
EVToEBITDA="0.247"
Beta="1.722"
num_52WeekHigh="9.89"
num_52WeekLow="0.527"
num_50DayMovingAverage="0.955"
num_200DayMovingAverage="2.077"
SharesOutstanding="44296400"
DividendDate="None"
ExDividendDate="None"
symbol="EIGR"
open="0.79"
high="0.82"
low="0.75"
price="0.78"
volume="84401.00"
latest_trading_day="2023-07-21"
previous_close="0.80"
change="-0.02"
change_percent="-2.2875%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="79"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="21"
Volume_recent_avg="448907"
Change_recent_avg="-0.01"
Delta_recent_avg="0.1"
Variance_recent_avg="0.05"
Change_ratio_recent_avg="-1.5"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="21"
Aroon_momentum_negative="79"
image_negative_thumbnail_id_1="158"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0018.jpeg"
image_negative_thumbnail_id_2="1134"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0167.jpeg"
image_neutral_thumbnail_id_1="522"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0077.jpeg"
image_neutral_thumbnail_id_2="572"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0027.jpeg"
image_positive_thumbnail_id_1="953"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0115.jpeg"
image_positive_thumbnail_id_2="624"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0084.jpeg"
image_professor_thumbnail_id_1="1199"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0033.jpeg"
image_professor_thumbnail_id_2="1170"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0004.jpeg"
